200184-87-8

Basic information

• Product Name: CIS-BOC-4-METHOXY-D-PROLINE
• Synonyms: CIS-BOC-4-METHOXY-D-PROLINE;(2R,4R)-1-(TERT-BUTOXYCARBONYL)-4-METHOXYPYRROLIDINE-2-CARBOXYLIC ACID
• CAS NO: 200184-87-8
• Molecular Formula: C₁₁H₁₉NO₅
• Molecular Weight: 245.27
• Mol File: 200184-87-8.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: CIS-BOC-4-METHOXY-D-PROLINE(CAS DataBase Reference)
• NIST Chemistry Reference: CIS-BOC-4-METHOXY-D-PROLINE(200184-87-8)
• EPA Substance Registry System: CIS-BOC-4-METHOXY-D-PROLINE(200184-87-8)

Safety Data

• Hazardous Substances Data: 200184-87-8(Hazardous Substances Data)

Upstream product

• 200184-86-7 (2R,4R)-1-tert-butyl 2-methyl 4-methoxypyrrolidine-1,2-dicarboxylate 
• 135042-12-5 (4R)-1-(tert-butoxycarbonyl)-4-hydroxy-D-proline 
• 74-88-4 methyl iodide 

Downstream Products

• 200184-86-7 (2R,4R)-1-tert-butyl 2-methyl 4-methoxypyrrolidine-1,2-dicarboxylate 
• 910823-59-5 (2R,4R)-2-[2-fluoro-4-(2-oxo-pyridin-1-yl)-phenylcarbamoyl]-4-methoxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 536747-44-1 (2R,4R)-2-[2-Fluoro-4-(3-methyl-pyrazol-1-yl)-phenylcarbamoyl]-4-methoxy-pyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

HUMAN PLASMA KALLIKREIN INHIBITORS

Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

STEREOSELECTIVE SYNTHESIS OF N-PROTECTED ALKOXY PROLINES

A process for preparing optically-active N-protected alkoxy prolines, including (2R,4R)-4-methoxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester is disclosed. The N-protected alkoxy prolines are useful for preparing various serine protease factor Xa

QUINAZOLINE DERIVATIVES

The invention concerns quinazoline derivatives of Formula (I) wherein each of R1, R3, R20, X1, X2, Z, W, (a) and (q) have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of turnours which are sensitive to inhibition of erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.